In conclusion, here we demonstrate a substantial concordance rate (78.3%) of the expression of PD-L1 (detected using the 22C3 clone) between EBUS-TBNA and matched TBB specimens collected from advanced lung cancer patients, and that the PD-L1 expression levels correlate with the clinical efficacy of ICIs in the treatment of NSCLC. The gene discussed is CD274; the disease is lung cancer.